| 4.89 -0.29 (-5.6%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.81 |
1-year : | 7.53 |
| Resists | First : | 5.83 |
Second : | 6.44 |
| Pivot price | 5.34 |
|||
| Supports | First : | 4.84 |
Second : | 4.02 |
| MAs | MA(5) : | 5.13 |
MA(20) : | 5.42 |
| MA(100) : | 5.69  |
MA(250) : | 3.66 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 25.9 |
D(3) : | 30.8 |
| RSI | RSI(14): 35.9 |
|||
| 52-week | High : | 7.44 | Low : | 0.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZURA ] has closed above bottom band by 4.9%. Bollinger Bands are 24.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.21 - 5.23 | 5.23 - 5.26 |
| Low: | 4.77 - 4.81 | 4.81 - 4.84 |
| Close: | 4.84 - 4.89 | 4.89 - 4.94 |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Wed, 06 May 2026
JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) — 4.7% stake - Stock Titan
Mon, 04 May 2026
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fri, 01 May 2026
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Thu, 30 Apr 2026
[DEF 14A] Zura Bio Ltd Definitive Proxy Statement - Stock Titan
Mon, 27 Apr 2026
ZURA News | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Thu, 23 Apr 2026
Zura Bio Ltd - Eric Hyllengren separated from Zura Bio Limited as CFO on April 20, 2026 - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 21.1 (%) |
| Held by Institutions | 56.4 (%) |
| Shares Short | 6,150 (K) |
| Shares Short P.Month | 5,110 (K) |
| EPS | -1.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | -52.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -65 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -4.62 |
| PEG Ratio | 0 |
| Price to Book value | 3.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|